Five-Year Follow-Up of Intracoronary Autologous Cell Therapy in Acute Myocardial Infarction: The REGENERATE-AMI Trial
ESC Heart Failure2022Vol. 9(2), pp. 1152–1159
Citations Over TimeTop 10% of 2022 papers
Anthony Mathur, Doo Sun Sim, Fizzah Choudry, Jessry Veerapen, Martina Colicchia, Tymoteusz Turlejski, Mohsin Hussain, Stephen Hamshere, Didier Locca, Roby Rakhit, Tom Crake, Jens Kastrup, Samir Agrawal, Daniel A. Jones, John Martin
Abstract
This 5 year follow-up analysis of the REGENERATE-AMI trial did not show an improvement in clinical outcomes for patients treated with cell therapy. This contrasts with the 1 year results which showed improvements in the surrogate outcome measures of ejection fraction and myocardial salvage index.
Related Papers
- → A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia(2002)434 cited
- → Death, mode of death, morbidity and requirement for rehospitalization during 2 years after coronary artery bypass grafting in relation to preoperative ejection fraction(1996)9 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- → Ιστορική εξέλιξη της έννοιας του placebo από τα μέσα του 19ου αιώνα μέχρι σήμερα(2006)
- → Changes in Left Ventricular Ejection Fraction (LVEF) Predict Mortality in Heart Failure Patients With Reduced Ejection Fraction(2023)